Kalaris Therapeutics, Inc. (KLRS)

Kalaris Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	100.97	1.64	3.17	3.06
Cash & Short-Term Investments	100.97	1.64	3.17	3.06
Cash Growth	3200.59%	-48.28%	3.60%	-
Prepaid Expenses	1.22	0.97	0.16	0.84
Total Current Assets	102.18	2.61	3.33	3.9
Long-Term Deferred Charges	-	3.15	-	-
Other Long-Term Assets	0.91	0.41	-	-
Total Assets	103.09	6.16	3.33	3.9
Accounts Payable	2.37	1.56	2.36	2.75
Accrued Expenses	4.54	2.13	1	2.52
Short-Term Debt	-	19.91	-	-
Other Current Liabilities	0.23	1.11	0.58	0.42
Total Current Liabilities	7.14	24.7	3.94	5.69
Long-Term Debt	-	-	-	3.25
Other Long-Term Liabilities	32.08	32.08	-	0.26
Total Liabilities	39.22	56.78	3.94	9.21
Additional Paid-In Capital	190.63	19.95	2.38	2.42
Retained Earnings	-126.76	-116.56	-47.39	-32.7
Total Common Equity	63.87	-96.62	-45.02	-30.27
Shareholders' Equity	63.87	-50.62	-0.61	-5.31
Total Liabilities & Equity	103.09	6.16	3.33	3.9
Total Debt	-	19.91	-	3.25
Net Cash (Debt)	100.97	-18.27	3.17	-0.19
Net Cash Per Share	13.81	-2.76	0.52	-0.04
Filing Date Shares Outstanding	18.7	18.7	6.76	4.44
Total Common Shares Outstanding	18.7	6.73	6.76	4.44
Working Capital	95.04	-22.1	-0.61	-1.79
Book Value Per Share	3.42	-14.36	-6.66	-6.81
Tangible Book Value	63.87	-96.62	-45.02	-30.27
Tangible Book Value Per Share	3.42	-14.36	-6.66	-6.81

Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q